Category: Health

The Food and Drug Administration (FDA) has recently authorized the first at-home treatment for skin repigmentation for vitiligo patients.

Based on data from two identical Phase 3 clinical trials revealed that 30% of patients using the cream regained at least 50% of skin repigmentation on their body and roughly 20% of patients regained at least 50% of repigmentation on their face after 24 weeks, the FDA announced the approval of Incyte’s ruxolitinib cream on July 18.

Background

Before the approval of ruxolitinib, whose brand name is Opzelura, Jim Lee, vice president of Incyte’s head inflammation and autoimmune department, stated that the only treatment options available to people with vitiligo were light therapy carried out in a doctor’s office. They may now apply the cream at home.

Disease or circumstance

The most prevalent kind of vitiligo is nonsegmental vitiligo. Depigmentation, or loss of pigment, occurs in regions of the skin as a result of the disorder. Depigmentation may appear on the hands, arms, face, neck, scalp, and places that frequently come into contact with objects or are rubbed, such as the lips and genitals.

It is thought that vitiligo is an autoimmune condition. The immune system seems to be attacking the skin’s pigment cells (melanocytes) in vitiligo patients. Numerous people who have vitiligo also have at least one additional autoimmune condition.

Effectiveness

Opzelura has been proven to be safe and effective in two clinical studies (NCT04052425 and NCT04057573). In both studies, nonsegmental vitiligo patients were randomized to receive Opzelura or a placebo twice daily for 24 weeks, with an additional 28 weeks of Opzelura therapy for all participants. Compared to 10% of placebo patients, 30% of Opzelura patients achieved at least a 75% improvement in the face Vitiligo Area Scoring Index after the 24-week treatment period.

Information on Safety

The most frequent side effects of Opzelura are acne, itching, and fever at the application site, as well as the common cold, headache, and urinary tract infection.

Opzelura shouldn’t be used alongside therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine.

Patients using JAK inhibitor therapy for inflammatory disorders are at an increased risk of serious infections, death, cancer, significant adverse cardiovascular events, and thrombosis.

The nonprofit scientific research organization IAVI and Moderna Inc. is a biotechnology company that launches mRNA HIV vaccines. Recently, they announced that they start a Phase 1 clinical trial of mRNA HIV vaccine antigen mRNA-1644 at the Family Health Research center in Kigali, Rwanda, and The Aurum Institute in Tembisa, South Africa. According to the CDC, About 1.2 million people in the United States had HIV at the end of 2019. The World Health Organization says 37.7 million people in the world had HIV in 2020.

The first vaccines were distributed Thursday at the George Washington University School of Medicine and Health Sciences in Washington, DC. Phase I trials will be starting at the Hope Clinic of Emory Vaccine Center in Atlanta. Also the Fred Hutchinson Cancer Research Center in Seattle, and the University of Texas Health Science Center in San Antonio.

The working method of the vaccine…

The vaccine is designed to work with white blood cells to turn into antibodies that can neutralize HIV. A booster shot is also being studied to work with the HIV vaccine. The human immunodeficiency virus (HIV) has managed to dodge the immune system for long decades. Scientists have made advancements in treatments, such as long-acting injectables for pre-and post-exposure prevention and treatment. HIV can develop into AIDS, which can be dangerous.  The immunogens antigens were developed by the International AIDS Vaccine Initiative and Scripps Research.

They will be delivered using the same messenger RNA or mRNA technology in Moderna’s successful COVID-19 vaccine. On May 18, Moderna and the International AIDS Vaccine Initiative announced the first clinical trial in Africa for a candidate HIV vaccine.

I think this is a revolutionary approach to HIV vaccine design and development, and I am hopeful that we are on the path to finally realize an HIV vaccine,” said Etienne Karita, MD, MSc, MSPH, the director of CFHR. 

A San Diego-based sustainable food startup, Planet Based Foods, is producing clean, nutrient-dense, plant-based meat alternatives. Now, the Company has decided to make its products globally available by launching on the world’s largest retailer, Amazon. A curated selection of Planet Based Foods’ innovative hemp-formulated products is now available for purchase on the Company’s Amazon store, including The Original Burger, Green Chili Southwest Burger, Breakfast Sausage Patty Hot, The Original Crumble, The Italian Sausage Crumble, and Variety Pack. Individual items are priced at $29 including free shipping while the Variety Pack is listed for $69.

Launching strategy

As part of its launch strategy, Planet Based Foods has partnered with Omni ePartners as its broker. Omni ePartners is a leading full-service Amazon agency focused on increasing product awareness and increasing sales on the online marketplace. OeP will participate in the creation and optimization of the company’s Amazon site, producing and delivering high-quality content and ongoing marketing support via Search engine optimization, Search engine marketing research, creative advertising campaigns, and other powerful brand practices.

“Launching on Amazon the largest e-commerce retailer in the world represents a very exciting milestone in the Company’s growth journey. Much like Google, modern consumers of today use Amazon as their go-to search engine for purchasing products, and our presence on the platform will be highly impactful in boosting brand awareness, achieving sales targets, and continuously driving customers to the Planet-Based Foods website,” said Planet Based Foods’ President and CEO Braelyn Davis.

What is Planet Based Foods?

Planet Based Foods was founded in 2019 in San Diego, California. Its fully owned subsidiary in San Diego, California, Planet Based Foods, is a producer of sustainable plant-based meat substitutes. With a vision to build a better nutritional system by giving people, hemp formulated food products today that support our planet where all Planet Based Foods products are 100% vegan.

Why does Planet Based Foods support hemp?

Hemp is widely recognized as one of the most versatile crops in the world. It requires less water than other traditional crops, regenerates the soil is naturally resistant to pests, diseases, and fungi, and is one of the most sustainable crops. Not only is it a good source of complete protein, but also high in fiber, B vitamins, manganese, phosphorus, magnesium, iron, and essential fatty acids. Hemp is good for people and the planet. It’s a really good superfood.

Read More: BLUEVIEW Launches the World’s First Biodegradable Shoe

WHO defines a near miss as “an error that has the potential to cause an adverse event (patient harm) but fails to do so because of chance or because it is intercepted”.

The desire to supply more out-patients care than inpatient care creates some difficult situations. For example, overcrowding in the outpatient clinics and problems in healthcare supply chains in Inventory management, are not new in hospitals. Nowadays to overcome and to intercept this situation, BlueIOT Real-Time Locating Structure is going to be introduced to Indonesian Hospital this spring.

Recently, Nordic Semiconductor has issued a statement about BlueIOT Technology Co., Ltd, a Beijing-based tracking technology company, opted for Nordic’s nRF52833 Bluetooth Low Energy (Bluetooth LE) advanced multiprotocol System-on-Chip (SoC) to provide the core processing and wireless connectivity for ‘BlueIOT’, a Bluetooth LE Angle-of-Arrival (AoA) tracking system.

The tracking system is designed for indoor use in health centers, chain stores, or expositions, for instance, as well as for tracking in warehouses and factories. The nRF52833 SoC-powered tags are just like apple air tags, can be placed in key locations throughout a facility, or attached to resources in a warehouse, allowing staff, patients, and customers to plot a route to their way to a specified item or location via the ‘BLUEIOT MAP’ app on a Bluetooth 4.0 (and later) Android smartphone or iOS. The app provides indoor navigation and path planning features as well as point-of-interest utility.

BlueIOT’s tracking system takes its accuracy level down to 0.1m, which is 10 times higher compared to traditional Bluetooth gadgets. With patented tracking gateways, its tracking system is compatible with all tags that are Bluetooth 4.0 or above and supports the high-precision tracking assistance for both internet-of-things (IoT) tags and location-based services (LBS) smartphones. The system also stands out for its features of high efficiency, low energy, low cost, and small size.

How BlueIOT is Solving Issues?

Overcrowding, lessen waiting times, and multiplying access to the services for patients are now possible, hospitals and long-term care facilities have seen expensive inventory go to waste, and unused materials tie up valuable storage space. Surplus stock, emergency “just-in-case” supplies, and shelf-life limitations all exacerbate these issues can be solved.

After the smart home ecosystem now it’s time for smart hospital patient monitoring, smart logistics, etc there is n number of possibilities to intercept multiple problems and make the best use of assets with BlueIOT. 

Read More: People With Autism: The Most Proscribed Disorder

Rare Disease Day—dive into the unknown and get to know about the rare diseases affecting millions of Americans and people all over the world. According to NORD, there are around 7,000 rare diseases amongst which more than nine percent do not have any cures. Amongst which 72% are genetic rare diseases. This gruesome consequence spikes an interest to raise awareness amongst people and shine a light on rare diseases which need equal amounts of treatments and support as any other disorder requires. 

All about NORD

NORD is a patient advocacy organization, working to help patients suffering from rare diseases and the originations that serve them. It’s dedicated to specifying rare diseases, treatment, and cure of rare diseases through programs including education, research, advocacy, and patient services. 

Rare Disease Day is held on Monday, 28th February.

Ways to Support the Program 

The organization allows supporters to join a virtual 5k to help and support the patients suffering from Rare Diseases and help the organization spread awareness regarding the same. NORD is trying to bring equality for people suffering from Rare Diseases. The New Hope Run Club and Avery’s Hope are joining hands to sponsor the event. The event costs $35 to participate in and it takes place Sunday, Feb. 27.

These events encourage the supporters to light up their rooms with Rare Disease colors as a motive to portray their support for the patients suffering. Urges to encourage people all over the globe to do the same for showcasing their support. 

Fire departments, police departments, sheriff’s offices, troopers, and EMS teams can “Light Up for Rare” as well. The organization asks for supporters to post videos on social media using the Hashtags like #RareDiseaseDay @RareDiseases #LightUpForRare. 

Virtual Event of NORD

The event encourages supporters to grab their favorite zebra print shirt or toss on a striped scarf and take part in NORD online for a community gathering marking the 12th annual Rare Disease Day! This one-hour event is supposedly packed with entertainment from a star-studded guest lineup and offers a place to connect and chat with other rare community members and allies. This is a free virtual event and interested individuals need to register for it. It will be held Monday, Feb. 28 from 1:30 p.m. – 2:30 p.m.

Read More: Remarkable Connection Between Spirituality and the Health

On 4th February, this World Cancer Day, the National Comprehensive Cancer Network (NCCN) unites with associations all across the world to attract attention to inequities in cancer care and work to handle them. “Close the care gap” is the new campaign conducted by the Union for International Cancer Control (UICC) that will promote equity in health care for different races/ethnicities, socioeconomic groups, sexual orientations, gender identities, regions, and more.

According to Robert W. Carlson, MD, Chief Executive Officer, NCCN:

The identity and address of a person should not determine the healthcare someone receives. Still, there are disparities in the health care received by the U.S. and other countries. There are differences in health care for different communities of people within the U.S. So this World Cancer Day, NCCN will discover and manage the important barriers that stop too many people from acquiring high-quality cancer care. 

Previously on World Cancer Day global strategy for eliminating cervical cancer was announced by World Health Organization. According to UICC, the survival rate of women with cervical cancer is more for white women than for black women in the U.S. The mortality rate for cervical cancer is more than 90% in low and middle-income households. Only 20% of the children from low-income households survive from cancer while the survival rate in high-income households is 80%.

There are significant differences between the cancer care received by different groups of people even in high-income countries like the U.S. So on World Cancer Day, NCCN and UICC tries to uncover and close the care gap received by different communities.

Dr. Cary Adams, CEO of UICC, says: 

Healthcare organizations should come together and break down barriers. Over the last 10 years, UICC has achieved a lot in cancer care and control around the world but not handling inequities in society is delaying their progress. Closing the care gap is about fairness, dignity, and fundamental rights to let everyone have better health and live a longer life.

The NCCN Guidelines in Oncology is a resource that standardizes the best available quality in cancer care and stops improper or insufficient management. Many separate studies reveal that standardized care enhances results, but is not always used equally for all patient groups.

READ MORE: Immorna Biotherapeutics, Inc. Expands R&D Footprint in RTP, NC